SecBot SecBot

RANI

Rani Therapeutics Holdings, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. CA· CIK 0001856725 Biotech & Drug Discovery
$0.5949 −0.01 (−1.83%)
Oct 26 4:00 PM ET · prev $0.6060
Market cap
$81.9M
Micro cap
Consensus
Buy
91% Buy or better · 11 analysts
Median target
🔒 Subscribers only
Next earnings
Nov 5
in 10 days · EPS est. −$0.05
1 year
−66.6%
from $1.78 · Oct 27
30 days
−23.3%
from $0.7760
52-week range
$0.5880–2.50
−76% from high · low Oct 22
Avg volume 20D
529.0K
shares / day
Short interest
7.25M
≈5.2% of shares · +1.9%
Days to cover
11.6
at average volume
Insider net
+$49.7K
2 buyers · 1 seller · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read MIXED 1 report · 90 days
Balance 0 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/1 ·Next Earnings date, Nov 5, 2026
Strongest NEUTRAL Rani Therapeutics appointed Michelle Gilson to its Board of Directors and as chair of the Audit Committee…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    2 insiders bought $50.0K at an average $0.7047. 1 insider sold $301.08. Price is 16% below their cost.

  • InstitutionsMIXED

    Q2 2026: 6 added (0 new), 5 trimmed or exited.

  • AnalystsBULLISH

    10 of 11 rate it Buy or better.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.055 → −$0.047 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest +1.9% to 7.25M shares. 11.6 days to cover, ≈5.2% of shares.

  • TrendDOWNTREND

    24% below its 50-day average. New closing low $0.5880 on Oct 22.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
JANE STREET GROUP, LLCDOUBLED485,899$369.5K
BlackRock, Inc.TRIM342,113$260.1K
UBS Group AGADD297,270$225.9K
SUSQUEHANNA INTERNATIONAL GROUP, LLPTRIM57,790$43.9K
Squarepoint Ops LLCDOUBLED41,902$31.9K
MORGAN STANLEYADD30,486$23.2K
FARALLON CAPITAL MANAGEMENT, L.L.C.TRIM20,700$15.7K
Zurcher Kantonalbank (Zurich Cantonalbank)ADD19,051$14.5K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

11 analysts
Buy 91% rate it Buy or better
Strong Buy2Buy8Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Oct 22, 2026Chardan Capital
MAINTAIN
MAINTAINBuy
Aug 21, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 18, 2026Chardan Capital
INITIATE
INITIATEBuy
May 20, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$50.0K
bought · 2 insiders
$301.08
sold · 1 insider
−15.6%
vs their $0.7047 cost
DateInsiderTypeValue
Sep 27, 2026
Javadi Alireza
Chief Technical Officer
TAX W/H$234.59
Sep 27, 2026
Imran Talat
Chief Executive Officer
TAX W/H$6.0K
Aug 3, 2026
Gilson Michelle
Director
AWARD247,200 sh
Jul 21, 2026
IMRAN MIR A
Director
BUY$24.8K
Jul 17, 2026
Maestas Nicholas
Chief Financial Officer
AWARD2,000,000 sh
Jul 17, 2026
Imran Talat
Chief Executive Officer
BUY$25.2K
Jun 27, 2026
Javadi Alireza
Chief Technical Officer
TAX W/H$228.66
Jun 27, 2026
Imran Talat
Chief Executive Officer
TAX W/H$5.9K

Earnings setup

Estimates
Nov 5
reports in 10 days
−$0.05
EPS estimate, this quarter
+15%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.05-$0.05–-$0.04+6.7%$1.3M
Next Q-$0.05-$0.06–-$0.04+0.0%$1.6M
Current FY-$0.17-$0.18–-$0.17+5.5%$6.3M
Next FY-$0.19-$0.20–-$0.17+10.9%$6.6M

Short side

FINRA· Sep 30, 2026
7,249,790
shares short
+1.9%
vs prior settlement
11.6
days to cover
≈5.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 13, 2026 Other
Rani Therapeutics to Participate in the Chardan Healthcare Conference
SAN JOSE, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc (Nasdaq: RANI),
Sep 27, 2026 Insider
Javadi Alireza surrendered for taxes 309 shares
Chief Technical Officer @ $0.7592 ($234.59)
Sep 27, 2026 Insider
Imran Talat surrendered for taxes 7,928 shares
Chief Executive Officer @ $0.7592 ($6.0K)
Aug 4, 2026 SEC
Rani Therapeutics appointed Michelle Gilson to its Board of Directors and as chair of the Audit Committee, effective…
8-K — Impact 2/10
Aug 3, 2026 Insider
Gilson Michelle was granted 247,200 shares
Director
Jul 15, 2026 Press
Rani Therapeutics reported positive initial Phase 1a data for RT-114, an oral RaniPill® capsule delivering a…
Impact 7/10
Jun 30, 2026 Inst.
JANE STREET GROUP, LLC — DOUBLED
485,899 shares ($369.5K)
Jun 30, 2026 Inst.
BlackRock, Inc. — TRIM
342,113 shares ($260.1K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
RANI Q3 2026 Earnings After Market Close — 2026-11-05
Recent
Oct 13, 2026
Press release
Rani Therapeutics to Participate in the Chardan Healthcare Conference
SAN JOSE, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc (Nasdaq: RANI), a clinical-stage biotherapeutics company focused…
Aug 31, 2026
Short interest
Short Interest: RANI down 22% to 6.4M shares
Settlement 2026-08-31 | Days to cover: 8.10 | ≈4.58% of shares outstanding (est.)
Aug 6, 2026
Earnings date
RANI Q2 2026 Earnings After Market Close — 2026-08-06
Aug 4, 2026
Press release
Rani Therapeutics Appoints Michelle Gilson to Board of Directors
~ Former Chief Financial Officer of Arcellx Brings Deep Capital Markets and Biotech Financial Leadership Experience ~ ~ Former Chief Financial…
Jul 15, 2026
FDA
Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing
SAN JOSE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company…

SecBot reports

2 filings · 3 press releases · 1 bullish · 0 bearish · 1 neutral
All RANI filing & press-release reports (5)